ABBV-066, DEUCRAVACITINIB
M24-541
Approved small_molecule active
Quick answer
ABBV-066, DEUCRAVACITINIB for Plaque Psoriasis is a Approved program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Plaque Psoriasis
- Phase
- Approved
- Modality
- small_molecule
- Status
- active